PCP
CLDX icon

Perbak Capital Partners’s Celldex Therapeutics CLDX Stock Holding History

Perbak Capital Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40,410
Closed -$822K – 307
2025
Q2 		$822K Buy
+40,410
New +$787K 0.19% 95

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perbak Capital Partners's CLDX Position: Q3 2025 in Review

Perbak Capital Partners sold out of Celldex Therapeutics (CLDX) in Q3 2025, closing a stake of 40,410 shares — an estimated $822K sold.

Perbak Capital Partners first reported a position in CLDX in Q2 2025 and held it in 1 quarter. The position peaked at $822K in Q2 2025. 184 funds tracked by Wall St. Rank hold CLDX as of Q3 2025.

  • Perbak Capital Partners reported no remaining Celldex Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Perbak Capital Partners sold 40,410 Celldex Therapeutics shares in Q3 2025, an estimated $822K.
  • Perbak Capital Partners first reported a position in Celldex Therapeutics in Q2 2025 and held it in 1 quarter.
  • Perbak Capital Partners's Celldex Therapeutics position peaked at $822K in Q2 2025.
  • 184 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2025.

Based on Perbak Capital Partners's 13F filing for Q3 2025, filed 13 Nov 2025.